SINCE 2009
OPERATING RECORD
Corporate identity and public records are available in the Legal Hub.
PURE-PLAY B2B CDMO · PUBLIC DUE DILIGENCE · PROJECT SCOPE
GLOBAL CDMO PORTFOLIO & CORPORATE EVIDENCE.
Olympia Biosciences™ is a pure-play B2B Contract Development and Manufacturing Organization based in Gdynia, Poland. Current public corporate and certificate records are available in the Legal Hub; product, evidence and deliverables are defined within the agreed project scope. We operate zero consumer brands.
THE PUBLIC EVIDENCE MATRIX.
Public diligence starts with current Legal Hub records and a project-specific evidence review.
PURE-PLAY B2B
ZERO CONSUMER BRANDS
Olympia Biosciences™ does not operate consumer supplement brands.
LEGAL HUB
CURRENT PUBLIC RECORDS
Certificate status and scope are published in the Legal Hub.
PROJECT EVIDENCE
ANALYTICAL STRATEGY
Qualified independent laboratories perform evidentiary testing where required.
OPERATING COVENANT
SCIENTIFIC TRUTH BEFORE REVENUE.
Project suitability is assessed against the available evidence, manufacturing constraints and the agreed scope before a production decision is made.
Scientific Validity
If a composition cannot survive peer-reviewed clinical scrutiny or physical-chemistry validation, we will not manufacture it, regardless of the budget.
Human Continuity
Consultation is led by the CEO or a dedicated Lead Project Manager, depending on project phase and requirements.
Aligned Outcomes
We do not hide behind the market operator's legal responsibility. We make sure our partner understands the risk, the evidence, and the decision before the product leaves our hands.
Human-Led, AI-Enabled
Before a pattern can be learned, someone has to see it first. Olympia turns that first insight into reproducible manufacturing detail and delivers the contracted, project-specific IP required for the client to own and scale the product. Automation provides precision; accountable people govern every critical decision. AI helps us search, test, map, and accelerate the work—it does not originate the scientific direction.
PUBLIC MANUFACTURING RECORD
ONE PUBLICLY DISCLOSED CASE.
Most client collaborations remain confidential. The Lycotec Ltd scale-up is a rare public exception because Adiuvo Investments disclosed the manufacturing role in the Carocelle programme in its annual reporting.
Adiuvo's 2016 and 2017 annual reports name IOC sp. z o.o. as the contract manufacturer of Carocelle capsules.
Two consecutive public reporting periods provide a directly verifiable manufacturing reference—without disclosing confidential client work.
PROJECT GOVERNANCE
SCIENTIFIC LEADERSHIP.
Founder Synthesis × Execution System
A project-specific route connects formulation evidence, manufacturing constraints, analytical strategy and agreed deliverables. The scope is reviewed before a production decision is made.
Enterprise-level formulation requires enterprise-level oversight. Depending on your project's phase and regulatory requirements, your strategic consultation will be led by our CEO or your dedicated Lead Project Manager.
Olimpia Baranowska
CEO & Scientific Director
M.Sc. Eng. in Technical Physics and Applied Mathematics; Ph.D. Candidate in Medical Sciences (Phlebology). Architect of Olympia's pure-play B2B CDMO model and AI-assisted formulation-evidence workflow featured in Forbes. Awarded International Leader in Scientific Excellence in Rome under the patronage of Poland's National Centre for Research and Development (NCBR).
Haris Haroon
Manager of B2B Sales & Strategic Project Management
Educated as a Medical Doctor and Surgeon (MBBS) with postgraduate training in Sports Management. He brings a clinical perspective into regulated-product manufacturing, regulatory alignment, and supply-chain execution.
Izabela Łagód
Manager of B2B Sales & Strategic Project Management
M.Sc. in Medical Biology with a specialization in Molecular and Biochemical Diagnostics. Her laboratory background spans advanced clinical research, molecular biology, and biochemical analysis, connecting molecular science with disciplined industrial execution.
PROPRIETARY TECHNOLOGY
INDUSTRIALIZED DELIVERY SYSTEMS.
Where technically suitable, Olympia evaluates delivery-system options within the project's formulation, manufacturing and evidence requirements. Suitability is determined through the agreed development scope.
Registered Innovation Assets
Registered innovation marks and their current ownership records are available through the Legal Hub.
Collagen Development Scope
Material selection, format and evidence needs are evaluated within the agreed development scope; suitability is not assumed before review.
Clean-Label Excipient Substitution
Where technically suitable, we evaluate plant-derived, clean-label alternatives to conventional anti-caking, flow, lubrication, and binding excipients. Every substitution undergoes rigorous formulation, stability, and market-specific validation.
Evidence and Analytical Strategy
Evidence review and analytical strategy are defined within the project scope. Qualified independent laboratories perform evidentiary testing where required.
THE FINAL GATE
INITIATE R&D DUE DILIGENCE.
Supplement Paid Discovery starts at €2,500 and converts an early brief into a defined, evidence-led development route. FSMP and medical-nutrition programmes are scoped and quoted individually. Contracted project deliverables are portable; reusable Olympia tools and any third-party transfer support remain governed by the signed scope.
Your 30-minute strategic consultation is confidential. Where appropriate, and subject to prior notice and participant consent, the session may use AI-assisted transcription to create an accurate operational record. Contractual commitments remain governed by signed documents.
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.